Timothi Van Mulder will present Novosanis' breakthrough results on the development of a painless injection device for children at 12th Vaccine Congress in Budapest, Hungary from September 16 to 19, 2018. His research on skin thickness in children from birth to adolescence as well as the preliminary prototype test results will be shown.
Novosanis is developing an innovative platform of intradermal injection devices, VAX-IDTM, both suited for children and adults. The platform aims to deliver medicines into the dermal layer of the skin in a painless and standardized manner. Novosanis engineered a vertical platform architecture, allowing for accurate delivery of the substances without the need of being medically trained.
In short, the dermal skin layer is the second uppermost layer of your skin providing humans a first barrier of invading micro-organisms guaranteed by specific immunogenic cells. In spite of the natural advantages of this skin layer, it is challenging to accurately deliver substances because of its physical character being thin. In adults it varies from 0.8 to 1.5 mm depending on the body site, for children limited scientific data was available.
Timothi Van Mulder, Clinical Affairs Manager at Novosanis, is dedicating his doctoral research to the development of a painless and accurate intradermal injection device suited for children. His research on skin thickness in children from birth to adolescence, as well as the preliminary prototype test results, will be shown during the 12th Vaccine Congress in Budapest, Hungary from September 16 to 19, 2018.